<table>
<thead>
<tr>
<th>First name</th>
<th>Last name</th>
<th>Consulting Fees / Honoraria</th>
<th>Clinical Trials</th>
<th>Other Financial Benefits</th>
<th>Relevance to Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Luc</td>
<td>Bigras</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Beth</td>
<td>Cummings</td>
<td>Pfizer Harris</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kevin</td>
<td>Harris</td>
<td>Janssen</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert</td>
<td>Hegle</td>
<td>Sanofi, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Novartis, Pfizer, Regeneron, Sanofi, Ultragenyx</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Melanie</td>
<td>Henderson</td>
<td>Sanofi, Love Therapeutics</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael</td>
<td>Khoury</td>
<td>Ultragenyx</td>
<td>Esperion Therapeutics</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brian</td>
<td>McCrindle</td>
<td>Amryt Pharma, Chiesi, Esperion, Ultragenyx</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Katherine</td>
<td>Morton</td>
<td>Novo Nordisk, Novo Nordisk Data Safety Monitoring Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Julie</td>
<td>St. Pierre</td>
<td>Novo Nordisk, Bausch &amp; Health</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter</td>
<td>Wong</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

**Consulting Fees / Honoraria**
- Advisory board to Pfizer related to growth hormone, Advisory Board status (peptide pumps)
- Advisory board to Pfizer related to growth hormone, Advisory Board status (peptide pumps)
- None
- None
- None
- None
- None
- None

**Clinical Trials**
- The Medicines Company, Regeneron, Novo Nordisk, Drug, Amgen
- Sanofi, Amgen, Arrowhead
- None
- None
- None
- None
- None
- None

**Other Financial Benefits**
- None
- None
- None
- None
- None
- None
- None
- None

**Relevance to Statement**
- None
- Advisory Board to Pfizer related to growth hormone, Advisory Board status (peptide pumps)
- None
- None
- None
- None
- None
- None

The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Updated March 8, 2023.